In short
This article discusses the ongoing clinical trials of mRNA-4359, a new drug being tested for the treatment of advanced solid tumors. The trials aim to evaluate the safety, effectiveness, and potential benefits of mRNA-4359 when used alone or in combination with another drug called pembrolizumab. The study focuses on patients with various types of advanced cancers, including melanoma and non-small cell lung cancer.
At a glance
- Drug Name
- mRNA-4359
- Drug Type
- Synthetic mRNA encapsulated in lipid nanoparticle
- Administration
- Intramuscular injection
- Trial Phase
- Phase 1/2
- Main Objective
- Assess safety and tolerability of mRNA-4359 alone and with pembrolizumab
- Secondary Objectives
- Assess antitumor activity and T cell profile changes
- Target Conditions
- Advanced solid tumors (melanoma, NSCLC, bladder cancer, etc.)
- Treatment Duration
- 9 cycles (27 weeks)
- Key Endpoints
- MTD, DLTs, AEs, ORR, DCR, DOR, PFS
What is MRNA-4359?
MRNA-4359 is a new experimental drug being developed to treat various types of advanced solid tumors. It is classified as an Advanced Therapy Medicinal Product (ATMP), which means it's a cutting-edge treatment that uses genetic materials to fight diseases. The drug is also known by another name, CX-029440.
How Does MRNA-4359 Work?
MRNA-4359 uses a technology called messenger RNA (mRNA). Here's a simplified explanation of how it works:
- The drug contains synthetic mRNA wrapped in tiny fat bubbles called lipid nanoparticles.
- This mRNA carries instructions to make small pieces of two important proteins: IDO1 and PDL1 (also known as CD274).
- When injected into the body, these proteins can help stimulate the immune system to fight cancer cells.
It's important to note that MRNA-4359 doesn't change your genes. The mRNA stays outside the cell's nucleus (where your DNA is kept) and doesn't alter your genetic makeup.
What Conditions Does MRNA-4359 Treat?
MRNA-4359 is being studied to treat various types of advanced solid tumors. These include:
- Cutaneous melanoma: A type of skin cancer
- Non-small cell lung carcinoma (NSCLC): The most common type of lung cancer
- Non-muscle invasive bladder cancer: Cancer in the inner lining of the bladder
- Head and neck squamous cell carcinoma: Cancer in the cells lining the mouth, nose, and throat
- Microsatellite stable colorectal cancer (MSS CRC): A type of colon or rectal cancer
- Basal cell carcinoma: Another type of skin cancer
- Triple negative breast cancer: An aggressive type of breast cancer
Clinical Trial Information
MRNA-4359 is currently being tested in a Phase 1/2 clinical trial. This means it's in the early stages of testing in humans to determine its safety and effectiveness. The trial has several main goals:
- To assess how safe MRNA-4359 is when used alone or combined with another drug called pembrolizumab.
- To see how well MRNA-4359 works against tumors, both alone and with pembrolizumab.
- To understand how MRNA-4359 affects T cells (a type of immune cell) in the body and in tumors.
Who Can Participate in the Trial?
The trial is looking for adults with specific types of advanced cancers. Some key points about who can participate:
- Participants must have confirmed advanced or metastatic cancer (cancer that has spread to other parts of the body).
- For some parts of the trial, participants must have cancers that haven't responded to previous treatments, including immunotherapy.
- Participants need to be in relatively good health overall, with an ECOG performance status of 1 or less. This means they should be able to carry out light work.
There are also several reasons why someone might not be able to participate, such as having active brain tumors, certain other medical conditions, or being pregnant or breastfeeding.
What to Expect During the Trial
The trial is divided into different "arms" or groups:
- Arm 1a: Participants receive MRNA-4359 alone.
- Arm 1b and Pharmacodynamic (PD) Arms: Participants receive MRNA-4359 combined with pembrolizumab.
- Arm 2: For patients who haven't had any previous treatment for their cancer.
The treatment period lasts for 9 cycles (about 27 weeks). MRNA-4359 is given once every three weeks, while pembrolizumab (when used) is given once every six weeks.
Potential Benefits and Risks
As with any experimental treatment, there are potential benefits and risks:
Potential Benefits:
- The treatment might help slow down or stop tumor growth.
- It could potentially work for patients whose cancers haven't responded to other treatments.
Potential Risks:
- As this is a new treatment, there might be unknown side effects.
- The treatment might not work for everyone.
It's important to discuss these potential benefits and risks thoroughly with your healthcare provider if you're considering participating in this clinical trial.
